Lisata Therapeutics (NASDAQ:LSTA) Shares Down 5.1% – Time to Sell?

Lisata Therapeutics, Inc. (NASDAQ:LSTA)’s stock price traded down 5.1% on Monday. The company traded as low as $1.50 and last traded at $1.50. 38,180 shares were traded during mid-day trading, a decline of 88% from the average daily volume of 306,459 shares. The stock had previously closed at $1.58.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised Lisata Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. Two analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Reduce”.

Lisata Therapeutics Price Performance

The stock has a market capitalization of $13.16 million, a P/E ratio of -0.91 and a beta of 0.94. The company’s 50 day simple moving average is $1.46 and its two-hundred day simple moving average is $2.95.

Lisata Therapeutics (NASDAQ:LSTA) last posted its earnings results on Thursday, August 6th. The company reported ($0.32) earnings per share (EPS) for the quarter. On average, research analysts anticipate that Lisata Therapeutics, Inc. will post -1.09 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lisata Therapeutics

Several institutional investors have recently bought and sold shares of LSTA. BlackRock Inc. bought a new stake in shares of Lisata Therapeutics during the second quarter worth $1,730,000. GSA Capital Partners LLP bought a new position in shares of Lisata Therapeutics in the second quarter valued at about $321,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Lisata Therapeutics during the 2nd quarter worth about $157,000. Deltec Asset Management LLC acquired a new position in Lisata Therapeutics during the 1st quarter worth about $451,000. Finally, Rangeley Capital LLC bought a new stake in Lisata Therapeutics during the 1st quarter worth about $376,000. Institutional investors own 8.94% of the company’s stock.

About Lisata Therapeutics

Lisata Therapeutics, Inc (NASDAQ:LSTA) is a clinical-stage biotechnology company focused on developing therapies for the treatment of cancer. The company’s research is centered on improving the delivery of anticancer agents into solid tumors and addressing the biological barriers that can limit the effectiveness of conventional cancer treatments.

Lisata’s lead investigational product is certepetide, formerly known as LSTA-1. Certepetide is a tumor-penetrating peptide designed to selectively bind to neuropilin-1, a receptor associated with tumor vasculature and the tumor microenvironment.